ReviewExperimental biology and medicine (Maywood, N.J.)2021
CD9, a tetraspanin target for cancer therapy?
Review in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 65 citations in OpenAlex.
- Midkine and CA9 Are Potential Cancer Stem Cell Biomarkers in Triple-Negative Breast Tumours.Analytical cellular pathology (Amsterdam) · 2026Article
- Exosome crown proteins are promising markers for liquid biopsy of breast cancer.Frontiers in oncology · 2026Review
- CD9-positive tumor-associated macrophages promote renal cell carcinoma progression by activating the orphan nuclear receptor Nor1/Nr4a3.Cancer cell international · 2025Article
- Review
- Tumor-derived exosomes and their application in cancer treatment.Journal of translational medicine · 2025Review
- Extracellular membrane particles en route to the nucleus - exploring the VOR complex.Biochemical Society transactions · 2025Review
- Distinctive Features of Extracellular Vesicles Present in the Gastric Juice of Patients with Gastric Cancer and Healthy Subjects.International journal of molecular sciences · 2025Article
- CD9, a novel potential biomarker of sarcopenia.Scientific reports · 2025Article
- Hypoxic endometrial epithelial cell-derived microRNAs effectively regulate the regenerative properties of mesenchymal stromal cells.World journal of stem cells · 2025Article
- Construction and validation of a transmembrane 4 superfamily-related genes prognostic model for esophageal squamous cell carcinoma.Frontiers in oncology · 2025Article
- CD9 expression rivals IDH mutation as a prognostic marker in glioma: a novel nomogram approach.Frontiers in neurology · 2025Article
- Bioinformatics investigation of the prognostic value and mechanistic role of CD9 in glioma.Scientific reports · 2024Article
- CD9 promotes TβR2-TβR1 association driving the transition of human dermal fibroblasts to myofibroblast under hypoxia.Molecular medicine (Cambridge, Mass.) · 2024Article
- Innovative Therapeutic Delivery of Metastasis-Associated in Colon Cancer 1-Suppressing miRNA Using High Transmembrane 4 L6 Family Member 5-Targeting Exosomes in Colorectal Cancer Mouse Models.International journal of molecular sciences · 2024Article
- Article
- Article
- Extracellular lipidosomes containing lipid droplets and mitochondria are released during melanoma cell division.Cell communication and signaling : CCS · 2024Article
- Review
- Quantitative Detection of Biological Nanovesicles in Drops of Saliva Using Microcantilevers.ACS applied materials & interfaces · 2024Article
- CD9 exacerbates pathological cardiac hypertrophy through regulating GP130/STAT3 signaling pathway.iScience · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the present minireview, we intend to provide a brief history of the field of CD9 involvement in oncogenesis and in the metastatic process of cancer, considering its potential value as a tumor-associated antigenic target. Over the years, CD9 has been identified as a favorable prognostic marker or predictor of metastatic potential depending on the cancer type. To understand its implications in cancer beside its use as an antigenic biomarker, it is essential to know its physiological functions, including its molecular partners in a given cell system. Moreover, the discovery that CD9 is one of the most specific and broadly expressed markers of extracellular membrane vesicles, nanometer-sized entities that are released into extracellular space and various physiological body fluids and play a role in intercellular communication under physiological and pathological conditions, notably the establishment of cancer metastases, has added a new dimension to our knowledge of CD9 function in cancer. Here, we will discuss these issues as well as the possible cancer therapeutic implications of CD9, their limitations, and pitfalls.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.